2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
Open accessThe DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index; 152 of the 254 sources its claims cite were checked for support.
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
CoChat Summary
TL;DR
This ADA Standards of Care chapter provides updated recommendations for diagnosing and classifying diabetes, prediabetes, and related forms, including diagnostic thresholds, screening intervals, and classification categories. It emphasizes confirmatory testing, A1C limitations, risk-based screening, and special populations such as type 1 diabetes, gestational diabetes mellitus (GDM), cystic fibrosis–related diabetes (CFRD), posttransplantation diabetes mellitus (PTDM), pancreatic diabetes, and monogenic diabetes.
Key findings
- Diabetes diagnostic criteria: A1C ≥6.5% (≥48 mmol/mol), FPG ≥126 mg/dL (≥7.0 mmol/L), 2-h PG ≥200 mg/dL (≥11.1 mmol/L) during 75-g OGTT, or random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic hyperglycemic symptoms/crisis; absent unequivocal hyperglycemia, diagnosis requires two abnormal results. Prediabetes is defined by A1C 5.7–6.4% (39–47 mmol/mol), FPG 100–125 mg/dL (5.6–6.9 mmol/L; IFG), or 2-h PG 140–199 mg/dL (7.8–11.0 mmol/L; IGT).
- Classification includes type 1 diabetes (5–10% of diabetes), type 2 diabetes (90–95%), specific types due to other causes, and GDM. Misdiagnosis is common and can occur in ~40% of adults with new type 1 diabetes; type 1 diabetes staging shows ~44% 5-year risk of symptomatic disease at stage 1 and ~60% risk by 2 years and ~75% within 5 years at stage 2.
- Screening: begin at age 35 years for all adults; consider earlier in adults with overweight/obesity plus one or more risk factors; repeat at minimum 3-year intervals if normal. In children/adolescents, consider risk-based screening after puberty or age 10 years, whichever is earlier, with overweight/obesity plus risk factors.
- Special populations: GDM screening at 24–28 weeks; one-step IADPSG criteria increase GDM diagnosis (e.g., 11.5% vs 4.9% in a 2021 USPSTF review) without demonstrated improved health outcomes. CFRD occurs in about 20% of adolescents and 40–50% of adults with cystic fibrosis; annual OGTT screening begins by age 10, and A1C is not recommended for screening due to low sensitivity. PTDM diagnosis is best made once stable on immunosuppression, usually at least 45 days after transplantation, with OGTT preferred. Monogenic diabetes accounts for <5% of diabetes; 80–85% of neonatal diabetes cases have a monogenic cause, and 30–50% of KATP-related neonatal diabetes improves with high-dose oral sulfonylureas.
Methods
- Design: ADA Standards of Care clinical practice guideline/consensus recommendations, updated annually by the ADA Professional Practice Committee, an interprofessional expert committee.
- Data/sample: No primary study sample; the chapter synthesizes published evidence and expert consensus. It references an ADA evidence-grading system (A/B/C/E) detailed in the Introduction and Methodology.
- Main analysis: Narrative synthesis of diagnostic, classification, and screening evidence with graded recommendations; no meta-analysis or primary data collection is reported in this chapter.
Limitations
- Stated evidence gaps include insufficient evidence for continuous glucose monitoring (CGM) for screening/diagnosis of prediabetes or diabetes; unknown optimal screening interval; uncertain benefit of treating early abnormal glucose metabolism; lack of randomized controlled trials for treating versus not treating GDM diagnosed by IADPSG but not Carpenter-Coustan criteria; and limited data on how treating maternal hyperglycemia affects offspring metabolic outcomes.
- Stated classification/diagnostic limitations include common misdiagnosis (e.g., ~40% of adults with new type 1 diabetes), poorly understood type 2 diabetes genetics, inadequate genetic data in diverse populations, and A1C unreliability in conditions such as hemoglobin variants, pregnancy, glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss/transfusion, or erythropoietin therapy.
- Evident from the text: this is a consensus guideline rather than a primary systematic review or meta-analysis; recommendations are graded A/B/C/E, with some based on expert consensus (E), and many cited studies are observational/cohort rather than randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 2.1 Flowchart for investigation of suspected type 1 diabetes in newly diagnosed adults, based on data from White European populations. 1 No single clinical feature con fi rms type 1 diabetes in isolation. 2 Glutamic acid decarboxylase (GAD) should be the primary antibody measured and, if negative, should be followed by islet tyrosine phosphatase 2 (IA-2) and/or zinc transporter 8 (ZnT8) where these tests are available. In individuals who have not been treated with insulin, antibodies against insulin may also be useful. In those diagnosed at < 35 years of age who have no clinical features of type 2 diabetes or monogenic diabetes, a negative result does not change the diagnosis of type 1 diabetes, since 5 -10% of people with type 1 diabetes do not have antibodies. 3 Monogenic diabetes is suggested by the presence of one or more of the following features: A1C < 58 mmol/mol ( < 7.5%) at diagnosis, one parent with diabetes, features of a speci fi c monogenic cause (e.g., renal cysts, partial lipodystrophy, maternally inherited deafness, and severe insulin resistance in the absence of obesity), and monogenic diabetes prediction model probability > 5% (diabetesgenes.org/exeter-diabetes-app/ModyCalculator). 4 A C-peptide test is only indicated in people receiving insulin treatment. A random sample (with concurrent glucose) within 5 h of eating can replace a formal C-peptide stimulation test in the context of classi fi cation. If the result is $ 600 pmol/L ( $ 1.8 ng/mL), the circumstances of testing do not matter. If the result is < 600 pmol/L ( < 1.8 ng/mL) and the concurrent glucose is < 4 mmol/L ( < 70 mg/dL) or the person may have been fasting, consider repeating the test. Results showing very low levels (e.g., < 80 pmol/L [ < 0.24 ng/mL]) do not need to be repeated. Where a person is insulin treated, C-peptide must be measured prior to insulin discontinuation to exclude severe insulin de fi ciency. Do not test C-peptide within 2 weeks of a hyperglycemic emergency. 5 Features of type 2 diabetes include increased BMI ( $ 25 kg/m 2 ), absence of weight loss, absence of ketoacidosis, and less marked hyperglycemia. Less discriminatory features include non-White ethnicity, family history, longer duration and milder severity of symptoms prior to presentation, features of the metabolic syndrome, and absence of a family history of autoimmunity. 6 If genetic testing does not con fi rm monogenic diabetes, the classi fi cation is unclear and a clinical decision should be made about treatment. 7 Type 2 diabetes should be strongly considered in older individuals. In some cases, investigation for pancreatic or other types of diabetes may be appropriate. 8 A person with possible type 1 diabetes who is not treated with insulin will require careful monitoring and education so that insulin can be rapidly initiated in the event of glycemic deterioration. 9 C-peptide values 200 -600 pmol/L (0.6 -1.8 ng/mL) are usually consistent with type 1 diabetes or maturity-onset diabetes of the young but may occur in insulin-treated type 2 diabetes, particularly in people with normal or low BMI or after long duration. Reprinted and adapted from Holt et al. (36).](https://figures.cochat.ai/paper-figures/7be96ed282694b1c85997763e16ae474/2-diagnosis-and-classification-of-diabetes-i-standards-of-care-in-diabetes2024-i-figure-1.png)

Verification
Claims the paper makes
99 Valid · 9 Not valid · 35 Not checked · 32 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However , in 2003 the ADA adopted the new range of 100 -125 mg/dL (5.6 -6.9 mmol/L) to better de fi ne IFG so that the population risk of developing diabetes with IFG would be similar to that with IGT (11).”
What the sources say
- Disputedcites [11] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care sourceExperimental — accuracy not yet measured
In “The new criteria” (p. 8), the committee defines IFG as fasting plasma glucose of 110 to <126 mg/dL, not 100–125 mg/dL. The paper describes both IFG and IGT as risk factors for future diabetes, but it does not say the lower IFG threshold was adopted to make their population risks similar. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In most cases, such stressor steroidinduced hyperglycemia resolves by the time of discharge (142,143).”
What the sources say
- Partly supportedcites [142] Thomas, 2000, Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes, BMC Nephrol sourceExperimental — accuracy not yet measured
The Results (Hyperglycaemia; page unavailable) show that mean glucose fell from immediately after surgery to the morning of day 2. The Discussion (page unavailable) describes steroid exposure and postoperative hyperglycaemia, but the paper does not report whether most patients’ hyperglycaemia resolved by discharge. (LLM, conf=0.82)
- Disputedcites [143] Chakkera, 2009, Hyperglycemia during the immediate period after kidney transplantation, Clin J Am Soc Nephrol sourceExperimental — accuracy not yet measured
The Abstract (Results) says hyperglycemia was sustained throughout hospitalization and that 66% of patients without pretransplantation diabetes required insulin at discharge. The Discussion says the authors did not know what proportion would ultimately recover, rather than finding that most cases resolved by discharge. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Because periodontal disease is associated with diabetes, the utility of screening in a dental setting and referral to primary care as a means to improve the diagnosis of prediabetes and diabetes has been explored (108 -110)”
What the sources say
- Not checked — no full text of the sourcecites [108] Lalla, 2013, Dental findings and identification of undiagnosed hyperglycemia, J Dent Res source
- Not checked — no full text of the sourcecites [109] Lalla, 2011, Identification of unrecognized diabetes and pre-diabetes in a dental setting, J Dent Res source
- Supportedcites [110] Herman, 2015, Screening for prediabetes and type 2 diabetes in dental offices, J Public Health Dent source
The Discussion (page unavailable) describes periodontal disease and its sequelae as risk factors for dysglycemia, supporting the general association claimed. The paper’s own Results (page unavailable) found no association between clinical evidence of periodontitis and dysglycemia in its study sample, so it should not be cited as demonstrating that association in this cohort. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose (82).”
What the sources say
- Partly supportedcites [82] Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med sourceExperimental — accuracy not yet measured
The Abstract Conclusions state that glycated hemoglobin was more strongly associated than fasting glucose with cardiovascular disease risk, but only similarly associated with diabetes risk. The study population was community-based and included Black and White adults without diabetes. Page numbers are not provided in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The epidemiologic studies that formed the basis for recommending A1C to diagnose diabetes included only adult populations (112).”
What the sources say
- Could not verifycites [112] Cowie, 2010, Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006, Diabetes Care sourceExperimental — accuracy not yet measured
The introductory discussion (page unavailable) says an international expert committee recommended A1C for diagnosis, but does not give the ages of participants in the epidemiologic studies behind that recommendation. The Research Design and Methods section (page unavailable) includes participants aged 12 and older in this paper’s own analysis; that does not establish the ages in the studies the committee relied on. Searches for adult-only evidence and pediatric populations did not resolve the claim. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
74 more claims · 46 with their cited sources checked
Create a free account to see all 175 claims and to verify the 3 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 75
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HbA1c can be affected by some non-glycaemic factors, including anaemia due to iron deficiency or malaria, specific haemoglobin variants (eg, HbS and HbF), other haemoglobinopathies, polycythaemia due to living in high altitude, liver and kidney diseases, HIV, and specific drugs such as antiretroviral therapy for HIV.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many clinical guidelines recommend using a second confirmatory test for diabetes diagnosis and initiating treatment,6,21–23 although there is variation in this guidance.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measured
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Research works printed but not linked: 1
- International Diabetes Federation . IDF Diabetes Atlas, 10th edition. Brussels, Belgium, International Diabetes Federation, 2021. Accessed 26 September 2023. Available from https://www.diabetesatlas.org/atlas/tenth-edition/
Cited by
Items 801–900 of 2,029
Insenser, M. R., Nattero‐Chávez, L., Luque‐Ramírez, M., Quiñones, S. D. L., Quintero-Tobar, A., Samino, S., Amigó, N., Avendaño, B. D., Fiers, T., & Escobar-Morreale, H. F. (2024) · Metabolites · doi:10.3390/metabo14080436 · Cited by 2
“Eligible patients met the following criteria for T1D diagnosis: (a) history of ketoacidosis and/or diabetic autoimmunity, and (b) dependence on insulin for survival according to the American Diabetes Association guidelines [10].”
MethodGhusn, W., Salameh, Y., Mosleh, K. A., Shah, M., Storm, A. C., Dayyeh, B. K. A., & Ghanem, O. M. (2024) · Surgical Innovation · doi:10.1177/15533506241273368 · Cited by 2
Hoyos, W., Ruíz, R., & Hoyos, K. (2024) · TecnoLógicas · doi:10.22430/22565337.3061 · Cited by 2
U-shaped association between hemoglobin levels and albuminuria in US adults: a cross-sectional study
Yin, R., & Hu, Z. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04200-8 · Cited by 2
“Diabetes was defined as FBP ≥ 7 mmol/L or diagnosed by a doctor [15].”
Peivandi, S., Habibi, A., Hosseini, S. H., Khademloo, M., & Motamedi‐Rad, E. (2024) · Health Science Reports · doi:10.1002/hsr2.70080 · Cited by 2
“11 GDM prevalence is expected to rise globally.”
BackgroundYu, Q., Ye, J., Li, H., Wu, X., Xia, Y., & Deng, X. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s474007 · Cited by 2
Ursu, M., Stuparu-Crețu, M., Gurău, G., Nitoi, L. C., Nechita, A., & Arbune, M. (2024) · Children · doi:10.3390/children11101162 · Cited by 3
Dyslipidemia in latent autoimmune diabetes in adults: the relationship with vitamin D
Tsaryk, I., Pashkovska, N. V., Pankiv, V. І., & Pashkovskyy, V. M. (2024) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.20.5.2024.1420 · Cited by 3
The Challenges of Diagnosing Gestational Diabetes after Bariatric Surgery: Where Do We Stand?
Rodrigues-Martins, D., Nunes, I., & Monteiro, M. P. (2024) · Obesity Facts · doi:10.1159/000541623 · Cited by 6
“The ADA Standards of Care in Diabetes were recently updated; however, it does not include any special consideration regarding pregnant women after BMS [23].”
Moreno-Vargas, A. D., Andrade‐Cetto, A., Espinoza-Hernández, F. A., & Mata-Torres, G. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1436927 · Cited by 3
Li, Y., Chen, J., Man, Q., Wang, R., Mao, D., Li, M., Zhang, J., Hu, Y., & Yang, L. (2024) · Metabolites · doi:10.3390/metabo14110579 · Cited by 3
“The diagnosis of T2DM and pre-DM was based on the 2024 edition of the American Diabetes Association (ADA) criteria, Diagnosis and Classification of Diabetes: Standards of Care in Diabetes [22].”
Risk Factors and Prevention Strategies for Gestational Diabetes in Asian Populations
Pan, S.-Y., Huang, C.-J., & Cheng, H.-M. (2024) · JACC: Asia · doi:10.1016/j.jacasi.2024.08.013 · Cited by 2
Gupta, Y., Goyal, A., Ambekar, S., Kalaivani, M., Bhatla, N., & Tandon, N. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01662-y · Cited by 3
“…Normoglycemia was defined as FPG 100 mg/dl (5.6 mmol/l) and 2-h post-load plasma glucose 140 mg/dl (7.6 mmol/l) and HbA1c 5.7% (39 mmol/mol) [18] Blood pressure Hypertension was defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg and/or the use of antihypertensive drugs [19] Prehypertension was…”
InfluentialCaturano, A., Martino, A. D., Albanese, G., Coppola, C., Russo, V., Koudelková, K., Galiero, R., Rinaldi, L., Sardu, C., Marrone, A., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02406-x · Cited by 3
“…fasting plasma glucose value (with a requirement for at least two determi - nations), the 2-hour glucose value obtained during a 75-g oral glucose tolerance test, or a random glucose value coupled with classic hyperglycemic symptoms (e.g., polyuria, polydipsia, and unexplained weight loss) [10].”
Age and sex mark clinical differences in the presentation of pediatric type 1 diabetes mellitus
Gupta, E. A., Huang, X., VELASQUEZ, H. J., Golani, K., Siller, A. F., Minard, C. G., Tosur, M., & REDONDO, M. J. (2024) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2024-0451 · Cited by 2
Cohen, N., Toledano, Y., Shafir, M., Lavie, O., & Zilberlicht, A. (2024) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-024-07845-z · Cited by 2
“Currently, both the American College of Obstetrics and Gynecology (ACOG) and the American Diabetes Association (ADA) advises that individuals diagnosed with GDM undergo a postpartum screening test for T2DM/prediabetes, by administration of a 2-h, 75-g Oral Glucose Tolerance Test (75-g OGTT) [5, 6].”
InfluentialÖzcürümez, M. K., Weninger, J., Coşkun, A., Arzideh, F., Streichert, T., Torge, A., Sowa, J., Quast, C., Canbay, A. E., Plebani, M., et al. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-0970 · Cited by 2
“(iii) The close vicinity of the two decision limits, i.e. 5.6 and 6.9 mmol/L, implies that special attention must be paid to all causes of variations in glucose levels [6].”
InfluentialYuan, F., Fang, D., Xu, H., Nie, Y., Cai, W., & Gu, T. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101588 · Cited by 3
Gonzalez, A. R., Harrison, C., Hewitt, B., Meijer, J. L., & Vajravelu, M. E. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae845 · Cited by 2
Walter, K. S., Choksi, P. U., Papaleontiou, M., Wang, C. C. L., Gumber, R. I., & Park, J. M. (2024) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.2060 · Cited by 2
“1,2,18,20 Specifically, the 2020 Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for diabetes management in chronic kidney disease specifically highlights that due to a lack of adequate studies and infection risk in KTRs, the recommendation to treat those with T2DM,…”
Modern-Day Management of the Dysglycemic Continuum: An Expert Viewpoint from the Arabian Gulf
Alessa, T., Alawadi, F., Alkaabi, J., Al-Mamari, A., Al‐Ozairi, E., Alromaihi, D., Elhadd, T. A., Gunaid, A. A., Hassanein, M. M., Jayyousi, A., et al. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s491591 · Cited by 3
“12 Weight loss through lifestyle modification is often difficult to maintain over the long term 34 and pharmacologic treatment may be required for the management of prediabetes where lifestyle intervention is insufficient.”
InfluentialCabral, B., Galdino, O. A., Gomes, I. D. S., Alves, J. S. F., Marques, J. I., de Souza, K. S. C., da Silva, R. M., Abreu, B. J., Lopes, N. P., Zucolotto, S. M., et al. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106638 · Cited by 4
Zhang, Z. H., Chen, Z., Song, R. D., & Jiang, T. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07642-2 · Cited by 4
Association between type 2 diabetes and periodontitis: a population-based study in the North Peru
Mayta-Mayorga, M., Guerra-Rodríguez, V., & Bernabé‐Ortiz, A. (2024) · Wellcome Open Research · doi:10.12688/wellcomeopenres.23036.3 · Cited by 2
Kang, X., Zhou, L., Zhang, Y., Kang, C., & Xue, J. (2025) · Scientific Reports · doi:10.1038/s41598-024-84282-7 · Cited by 3
Leonel, L. D. S., Wolin, I. A. V., Danielevicz, A., Diesel, M., Constantini, M. I., de Oliveira, J. B., Souza, A. A., Reichert, T. L., Silveira-Rodrigues, J. G., Soares, D. D., et al. (2025) · Trials · doi:10.1186/s13063-024-08660-2 · Cited by 3
“Therefore, reducing insulin resistance and improving glycemic control are the primary objectives in the therapeutic management of T2D [5].”
Kumthekar, P., Upadhyay, M., Tamma, R. R., Kranti, V., Bhattacharya, R., Sharma, P. K., Barge, V. B., Revankar, S. Y., & Ghatge, S. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_169_24 · Cited by 2
Renal functional reserve in living kidney donors
Rinne, A. G., Sørensen, C. A., Reseghetti, E., Rivero, Y., Rincón, M., Izquierdo, E. M., Bethencourt, A. A., Morales, A., Cabello, E., González, S., et al. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf053 · Cited by 2
Avogaro, A., Buzzetti, R., Candido, R., Cosmo, S. D., Notarianni, L., Consolo, E., & Luciano, M. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112055 · Cited by 3
Tripathi, P., KADAM, N. S., Kathrikolly, T., Tiwari, D., VYAWAHARE, A. R., Sharma, B., GANLA, M. H., Kuppusamy, M., Vijayakumar, V., & Saboo, B. (2025) · Scientific Reports · doi:10.1038/s41598-025-94694-8 · Cited by 8
“The inclusion criteria were age between 18 and 70 years and a confirmed diagnosis of T2D according to the American Diabetes Association (ADA) guidelines 9 .”
Arroyo, M. M., Gallegos, I. R., Paublini, H., López‐González, Á. A., López, P. J. T., Sánchez, C. M., Sastre-Alzamora, T., & Ramírez‐Manent, J. I. (2025) · Medicina · doi:10.3390/medicina61040613 · Cited by 2
“…based on the criteria established by the American Diabetes Association (ADA): fasting glucose levels below 100 mg/dL were considered normal, while values between 100 and 125 mg/dL indicated prediabetes or impaired fasting glucose, and readings exceeding 125 mg/dL were indicative of diabetes [47].”
Krysiak, R. G., Kowalcze, K. E., & Okopień, B. (2025) · Neuroendocrinology · doi:10.1159/000545525 · Cited by 2
“Both diabetes and prediabetes were diagnosed on the basis of criteria of the American Diabetes Association [29].”
Zhu, M., Xu, M.-Z., Li, C., Wang, J., Li, C., Gong, Y.-Q., Jin, J., Lü, K., & Hao, Y.-M. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1564957 · Cited by 2
“Based on the recommendations of the American Diabetes Association (ADA), diabetes mellitus is diagnosed when FBG levels reach ≥ 7.0 mmol/L, while values between 5.6 and 6.9 mmol/L indicate prediabetes or IFG (47).”
InfluentialLi, C., Yuan, X., Huang, L., et al. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70090 · Cited by 2
Islam, Z., Yamamoto, S., Konishi, M., Kochi, T., Kabe, I., & Mizoue, T. (2025) · Journal of Sleep Research · doi:10.1111/jsr.70064 · Cited by 2
Shen, S.-H., Tsai, H., Li, Y., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14092963 · Cited by 2
“Patients with prediabetes were defined according to the American Diabetes Association criteria, as having impaired fasting glucose (fasting plasma glucose between 100 and 125 mg/dL) and/or an HbA1c level between 5.7% and 6.4% [26].”
InfluentialVera-Ponce, V. J., Vásquez-Romero, L. E. M., Zuzunaga-Montoya, F. E., Loayza-Castro, J. A., Hidalgo, J. R. A., & Carrillo, C. I. G. D. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01622-8 · Cited by 3
“The Adult Treatment Panel III (ATP III) and the International Diabetes Federation (IDF) offer different cut-off points for abdominal obesity [6, 7], while the American Diabetes Association (ADA) and the World Health Organization (WHO) propose distinct thresholds for defining hyperglycemia [8, 9].”
Rohayem, J., Cunningham, O., Williams, D., Wistuba, J., McCarthy, L., Barrett, T. G., & Dias, R. P. (2025) · Andrology · doi:10.1111/andr.70049 · Cited by 2
Ferdina, A. R., Juhairiyah, Yuana, W. T., Setyawati, B., & Pangestika, D. E. (2025) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.040.01.21 · Cited by 14
Hariharan, R., Mousa, A., Menon, K., Feehan, J., Ukropcová, B., Ukropec, J., Schön, M., Majid, A., Aldini, G., de Courten, M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050630 · Cited by 2
“Key factors such as physical activity levels, pre-existing cognitive impairment, T2DM durations and diagnosis of T2DM using American Diabetes Association (ADA) guidelines, which incorporate HbA1c [48], should be carefully considered to ensure a more representative study population.”
Active Constituent of HQS in T2DM Intervention: Efficacy and Mechanistic Insights
Chen, Y., Wen, Q., Yang, B., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104578 · Cited by 2
“As a typical metabolic disease, type 2 diabetes mellitus (T2DM) often involves complex metabolic pathways, which pose challenges in investigating associated pathophysiological mechanisms and therapeutic interventions [2,3].”
Marconi, A. M., Alfieri, N., Garzia, E., Terzoni, S., Manodoro, S., & Catalano, P. M. (2025) · Nutrients · doi:10.3390/nu17111785 · Cited by 3
Health implications of prediabetes and the role of trace elements in insulin resistance
Amer, H. M., Aboelyazed, S., Elshafeey, F., & Elhalawany, S. H. (2025) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-025-00811-9 · Cited by 3
“The International Expert Committee (IEC) introduced a new HbA1 C-based definition of prediabetes with a range of 6.0% to 6.4% [15] which the ADA later adjusted to 5.7% to 6.4% in [13] .”
InfluentialDISH as a marker for incident diabetes mellitus in cardiovascular disease patients
Harlianto, N. I., Foppen, W., Hoesein, F. A. A. M., Hol, M. E., Verlaan, J., de Jong, P. A., Westerink, J., UCC-SMART Study group, Cramer, M. J., van der Meer, M. G., et al. (2025) · Rheumatology · doi:10.1093/rheumatology/keaf268 · Cited by 3
“Worldwide, the demand for radiological examinations continues to rise [18, 23], as well as a rise in the number of T2DM [24] and DISH cases.”
Pazos-Couselo, M., Lado‐Baleato, Ó., Izquierdo, V., Moreno-Fernández, J., Alonso‐Sampedro, M., Fernández‐Merino, C., & Gudé, F. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112286 · Cited by 3
Alsan, M. M., Cawley, J., Doyle, J. J., & Skelley, N. (2025) · AEA Papers and Proceedings · doi:10.1257/pandp.20251065 · Cited by 2
Zhou, Y., Wang, B., Wu, M., Hong, H., Li, G., & Xu, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-04502-6 · Cited by 2
Yu, T., Sun, F., Yu, W., Zhang, F., Wang, J., Shao, X., Liu, B., Yang, X., Chen, Y., Li, S., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1592463 · Cited by 2
Hu, T., Xu, Y., Li, X., Xiao, Y., Wang, Y., Ma, X., & Bao, Y. (2025) · European Journal of Cardiovascular Nursing · doi:10.1093/eurjcn/zvaf107 · Cited by 3
Luca, M. D., Ferrara, F., Gargani, L., et al. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.06.020 · Cited by 2
Chen, Z., Lin, C., & Zhang, J. (2025) · Allergy and Asthma Proceedings · doi:10.2500/aap.2025.46.250040 · Cited by 2
Peng, X., Huo, H., Gao, J., Jiang, X., & Yuan, Y. (2025) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.70031 · Cited by 2
“…included patients meeting the criteria for HCM with hemoglobin A1c (HbA1c) levels between 5.7% and 6.5%, the HCM with diabetes group included patients meeting the criteria for HCM and a diagnosis of diabetes based on HbA1c ≥ 6.5%, in accordance with the American Diabetes Association criteria [14].”
InfluentialKashif, A. R. M., & Meriton Stanly, A. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_21_25 · Cited by 2
Characterization of Novel WFS1 Variants in Three Diabetes Pedigrees
Liu, C., Fang, H., Wang, D., Cheng, Y., Shi, P., Yu, C., Li, X., Zhao, H. J., Hou, W., Guo, Z.-K., et al. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70114 · Cited by 1
Martínez-Rodríguez, D., Salazar-Alonso, J., Castro-Abrego, A., Ávila-Gónzalez, D., Martínez-Alarcón, O., Molina-Hernández, A., Martínez-Juárez, A., Godoy-Morales, H. S., Lara-Barragán, D. E., Portillo, W., et al. (2025) · Histochemistry and Cell Biology · doi:10.1007/s00418-025-02400-6 · Cited by 2
Malmir, H., Hosseinpour‐Niazi, S., Gaeini, Z., Mirmiran, P., & Azizi, F. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01695-5 · Cited by 3
Malik, N., Deshpande, A., & Prasad, M. R. (2025) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-025-00500-2 · Cited by 2
Chen, Y., Chen, G., Liang, Y., Huang, H., Cai, Y., & Ni, X. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1586106 · Cited by 2
“Diabetes was defined as FPG ≥ 7 mmol/L or HBA1c ≥ 6.5%, based on the Standards of Care in Diabetes — 2024 (29).”
InfluentialJawad, A. N., Kadhim, K. A., Ali, Z. H., Fawzi, H. A., & Alzajaji, Q. B. (2025) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01537-3 · Cited by 2
“[27–29].”
Alenezi, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165673 · Cited by 2
“However, contemporary ADA Guidelines (2023) now recommend zirconia materials with supragingival margins and regular HbA1c monitoring for diabetic patients, marking a paradigm shift in prosthetic material selection [37].”
Fleury, E. S., Papandonatos, G. D., Manz, K. E., Pennell, K. D., Hall, A. M., Chen, A., Buckley, J. P., Yolton, K. A., Cecil, K. M., Lanphear, B. P., et al. (2025) · Pediatric Research · doi:10.1038/s41390-025-04322-4 · Cited by 2
Aida, H., Tanaka, M., Sato, T., Kawaharata, W., Matsumori, R., Hosaka, I., Akiyama, Y., Nakata, K., Kouzu, H., Hanawa, N., et al. (2025) · Hypertension Research · doi:10.1038/s41440-025-02374-x · Cited by 7
“Diabetes mellitus was diagnosed based on the guidelines of the American Diabetes Association [24]: fasting plasma glucose ≥ 126 mg/dL, HbA1c ≥ 6.5% or self-reported use of anti-diabetic agents.”
InfluentialKévin, A. J., Lauret, K., Famoussa, K., et al. (2025) · Open Journal of Internal Medicine · doi:10.4236/ojim.2025.154028 · Cited by 2
Skóra, A., Hajduk-Maślak, K., Galasińska, I., Michalik, B., Szypuła, A., & Sęk, M. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.62.006 · Cited by 3
Pitsiava, S., Dimakopoulos, G., Tsimihodimos, V., Kotsa, K., & Koufakis, T. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2364054 · Cited by 2
“…the following requirements: i. having received a diagnosis of T2D from a physician according to the guidelines of the American Diabetes Association [13], ii. having received SGLT2i treatment for at least 6 consecutive months, before enrollment in the study, iii. demonstrating good adherence to…”
MethodGrech, J. L., Norman, I. J., Azzopardi, C., Grixti, M., & Sammut, R. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-083235 · Cited by 1
“(meeting the diagnostic criteria of the American Diabetes Association (ADA)) 36 and attending the DEU or the DEC at Mater Dei Hospital on an outpatient basis.”
BackgroundRisk factors associated with the mortality of COVID‑19 in patients with type 2 diabetes mellitus
Carbajal, J., Ballon-Salcedo, C., Uribe-Cavero, L. J., et al. (2024) · World Academy of Sciences Journal · doi:10.3892/wasj.2024.277 · Cited by 2
Sionti, V., Charalambous, G., Papageorgiou, G., Simos, Y. V., Tsamis, K. I., Lakkas, L. S., Peschos, D., & Gourni, M. (2025) · Sci · doi:10.3390/sci7010009 · Cited by 3
García, A. R., Paterou, A., Doherty, R. P., Landry, L. G., Lee, M., Anderson, A. M., Scudder, C. L., Slawinski, H., Ferreira, R. C., Trzupek, D., et al. (2022) · medRxiv · doi:10.1101/2022.05.11.22274678 · Cited by 1
Diagnosing Hyperglycemia (GDM) in Pregnancy: Closing the Door after the Horse Has Bolted?Preprint
Yajnik, C. S., Bandyopadhyay, S. K., Bhat, D., Wagh, R. S. H., Yajnik, P., Ladkat, R., Coyaji, K., Osmond, C., & Fall, C. H. D. (2024) · medRxiv · doi:10.1101/2024.10.21.24315904 · Cited by 3
Koçyiğit, E., Karadağ, M. G., Aktürk, M., & Varis, A. (2025) · Research Square · doi:10.21203/rs.3.rs-5920397/v1 · Cited by 2
Nakamura, S., Inoue, R., & Narimatsu, H. (2025) · medRxiv · doi:10.1101/2025.05.21.25328057 · Cited by 2
Perioperative Management of the Patient with Diabetes Mellitus
Levesque, C. A. (2024) · Critical Care Nursing Clinics of North America · doi:10.1016/j.cnc.2024.05.003 · Cited by 1
Gender-Related Difference in Skin Oxygenation in Young Patients with Uncomplicated Type 1 Diabetes
Neubauer‐Geryk, J., Myśliwiec, M., & Bieniaszewski, L. (2024) · Biomedicines · doi:10.3390/biomedicines12071413 · Cited by 2
“Mild hypoglycemia was defined as a non-interventional glucose episode 54 mg/dL in the month before the survey [57].”
BackgroundMethodPrevalence of Diabetes Mellitus in People Living With HIV in Dammam, Saudi Arabia
Alsaeed, A. H., Aljanobe, A. H., Alhassan, S. H., Almulaify, M. S., Alkhalaf, A. M., & Alhaddad, M. J. (2024) · Cureus · doi:10.7759/cureus.63809 · Cited by 1
Laniado, N., Shah, P. D., Gallo, L. C., Daviglus, M. L., & Isasi, C. R. (2024) · Hispanic Health Care International · doi:10.1177/15404153241264770 · Cited by 1
Papakonstantinou, E., Alsab, V., Lympaki, F., Chanioti, S., Giannoglou, M., & Katsaros, G. I. (2024) · European Journal of Clinical Nutrition · doi:10.1038/s41430-024-01482-0 · Cited by 2
“The notably lower GL (GL = 6) of SFC signi fi es a favorable modi fi cation from the medium GL [11, 12] of WWC and CC, delineating SFC as a low-GL food option.”
InfluentialPereira, L. B., Schroeder, H. T., dos Santos, J. K., Capelari, P. C. B., Schaan, B. D., & Bock, P. M. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01456-z · Cited by 1
Cobo‐Vuilleumier, N., Lorenzo, P. I., Vázquez, E. M., López–Noriega, L., Nano, R., Piemonti, L., Martín, F., & Gauthier, B. R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1470881 · Cited by 2
2-es típusú cukorbetegség és Alzheimer-kór − közös mikrobiális gyökerek?
Fekete, C., Schandl, L., Tomasics, G., Egey, A., Kis, J. T., & Winkler, G. (2024) · Orvosi Hetilap · doi:10.1556/650.2024.33128 · Cited by 1
Gomez-Gramajo, F., Rivoira, M. A., Rodríguez, V. A., Vargas, G. E., Mesones, R. V., Zago, M. P., Boccaccini, A. R., & Gorustovich, A. A. (2024) · Biomedical Materials · doi:10.1088/1748-605x/ad8c8b · Cited by 3
“Diabetes mellitus (DM) is a chronic condition that occurs when blood glucose levels increase (hyperglycemia) because the body stops producing or does not produce enough insulin, or is unable to use insulin effectively [1, 2].”
Liu, L., Yang, Q., Shen, P., Wang, J., Zheng, Q., Zhang, G., & Jin, B. (2024) · Journal of Biomedical Research · doi:10.7555/jbr.38.20240267 · Cited by 1
Yen, I., Chen, S., Lin, C., Fan, K., Yang, C., Hsu, C., Kuo, C., Lin, M., Lyu, Y., Juan, H.-C., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14311 · Cited by 3
“Diabetes was de fi ned according to the recommendations of the American Diabetes Association (ADA) 17 : fasting plasma glucose (FPG) ≥ 126 mg/dL (7 mmol/L), 2 h postprandial plasma glucose (2 hPG) during an OGTT ≥ 200 mg/dL (11.1 mmol/L), or HbA1c ≥ 6.5%, or the current use of anti-diabetic medications.”
InfluentialSex-related Differences in Insulin Resistance in the Geriatric Population
Kant, R., Jha, D., Karna, G., Routhu, B., & Dhar, M. (2024) · Journal of The Indian Academy of Geriatrics · doi:10.4103/jiag.jiag_59_24 · Cited by 2
Wang, L., Wang, L., He, F., et al. (2024) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szae083 · Cited by 1
Microbiome analysis of serum extracellular vesicles in gestational diabetes patients
Chang, C., Bai, Y.-C., Jiang, H., Ma, Q.-W., Hsieh, C.-H., Liu, C.-C., Huang, H.-C., & Chen, T.-J. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02358-2 · Cited by 5
Ashoka, H., Pradeep, S., Nair, K., & Kareenhalli, V. V. (2024) · Mathematics in Medical and Life Sciences · doi:10.1080/29937574.2024.2431821 · Cited by 1
Zhang, Y., Liu, X., Yang, S., Yang, X., Shang, M., Zhang, Y., & Tian, L. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02427-6 · Cited by 2
Cidade-Rodrigues, C., Silva, B., Silva, V. B., Chaves, C., Mazeda, M. L., Araújo, A. P., Machado, C., Pereira, C. A., Gomes, V., Figueiredo, O., et al. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02450-1 · Cited by 1
Yang, M. J., Shangguan, Q., Xie, G., Sheng, G., & Yang, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1465242 · Cited by 2
Healy, A. M., Faherty, M. S., Ackerman, J., Leeds, B., Morell, M., Kim, R., Ackerman, A. L., & Gerome, J. M. (2025) · Women s Health Reports · doi:10.1089/whr.2024.0137 · Cited by 1
“27,28 The exception to this was patients who had blood sugar readings over 200 mg/dL after the 1 hour, 50-g test as they met criteria of GDM diagnosis per guidelines.”
Recurrent Acute Pancreatitis: Many Faces(/Facets) of a Challenging Disease
Yadav, D. K., Zyromski, N. J., Whitcomb, D. C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.01.249 · Cited by 1
Lee, J.-H., Ryu, H. E., Han, T., Park, B., Heo, S., & Kwon, Y. (2025) · Endocrine · doi:10.1007/s12020-025-04200-3 · Cited by 1
“Type 2 diabetes was de fi ned as a fasting plasma glucose level of 126 mg/dL or more, HbA1c level of 6.5% or more, or the current use of antidiabetic medication [15].”
InfluentialChemical components, antidiabetic and anticancer effects of Origanum species
Bay, M. N., Şen, A., & Bitiş, L. (2025) · Bütünleyici ve Anadolu Tıbbı Dergisi · doi:10.53445/batd.1618550 · Cited by 1
Santos, M. P., Azevedo‐Martins, A. K., Rodrigues, A. O., Aquino, N. S. S., & Evangelista, F. S. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.97 · Cited by 3
Mróz, M., Sadowska, D., Zarychta, M., Iwanowicz-Palus, G., Kretowski, A. J., & Cybulski, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14062093 · Cited by 2
“Depending on the pathophysiology, diabetes is classified into four categories, i.e., type 1 diabetes, type 2 diabetes, and other specific types of diabetes and gestational diabetes [3].”
InfluentialSwathi, N. L., P, V., Devadarshini, M., Mohammed, A. P., Jothieswari, D., Umar, M., Ali, S. M., Iqbal, J., & Pravallika, P. L. (2025) · Cureus · doi:10.7759/cureus.80890 · Cited by 1
Petrovska, L., Kostitska, I. O., Petrovskyy, T., Petrovskyy, R., & Basiuha, I. O. (2025) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2025.1.02 · Cited by 2
Göbl, C. S., Linder, T., Eppel, D., Kotzaeridi, G., Weidinger, L., Zarotti, S., Fischer, T., Bernasconi, M. T., Kunze, M., Ochsenbein-Koelble, N., et al. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02490-7 · Cited by 4
“…at a follow-up visit between 24 and 28 weeks of gestation, whereby GDM was diagnosed if fasting, 60-min, or 120-min glucose concentrations exceeded the cut off values of 5.1 mmol/l (92 mg/dl), 10.0 mmol/l (180 mg/dl), and 8.5 mmol/l (153 mg/dl), according to international recom - mendations [6, 7].”
InfluentialJeong, S. I., Kim, H., & Kim, S. H. (2025) · BMC Pediatrics · doi:10.1186/s12887-025-05634-4 · Cited by 3
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Selvin, E., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Ekhlaspour, Laya
- Gaglia, Jason L.
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Selvin, Elizabeth
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S20-S42
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725812
- OpenAlex
- W4389560718
- Cited by
- 2,086
- References
- 232
- Citations by year
- 2026: 771 · 2025: 903 · 2024: 408 · 2023: 1
- FWCI
- 74.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetes diagnosis, diabetes classification, diabetes mellitus, clinical guidelines, American Diabetes Association standards of care, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.